Nature Reviews Microbiology, Journal Year: 2025, Volume and Issue: unknown
Published: May 13, 2025
Language: Английский
Biomolecules, Journal Year: 2025, Volume and Issue: 15(2), P. 270 - 270
Published: Feb. 12, 2025
The gut-brain-cancer axis represents a novel and intricate connection between the gut microbiota, neurobiology, cancer progression. Recent advances have accentuated significant role of microbiota metabolites in modulating systemic processes that influence both brain health tumorigenesis. This paper explores emerging concept metabolite-mediated modulation within connection, focusing on key such as short-chain fatty acids (SCFAs), tryptophan derivatives, secondary bile acids, lipopolysaccharides (LPS). While microbiota's impact immune regulation, neuroinflammation, tumor development is well established, gaps remain grasping how specific contribute to neuro-cancer interactions. We discuss with potential implications for neurobiology cancer, indoles polyamines, which yet be extensively studied. Furthermore, we review preclinical clinical evidence linking dysbiosis, altered metabolite profiles, tumors, showcasing limitations research gaps, particularly human longitudinal studies. Case studies investigating microbiota-based interventions, including dietary changes, fecal transplantation, probiotics, demonstrate promise but also indicate hurdles translating these findings therapies. concludes call standardized multi-omics approaches bi-directional frameworks integrating microbiome, neuroscience, oncology develop personalized therapeutic strategies patients.
Language: Английский
Citations
3
Advanced Science, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 27, 2025
Abstract This article provides an overview of the advancements in application fecal microbiota transplantation (FMT) treating diseases related to intestinal dysbiosis. FMT involves transfer healthy donor into patient's body, aiming restore balance and thereby treat a variety such as recurrent Clostridioides difficile infection (rCDI), inflammatory bowel disease (IBD), constipation, short syndrome (SBS), irritable (IBS). While has shown high efficacy treatment rCDI, further research is needed for its other chronic conditions. elaborates on mechanisms dysbiosis, well discusses key factors influencing effectiveness FMT, including selection, recipient characteristics, protocols, methods assessing microbiota. Additionally, it emphasizes successful FMT. Future should focus optimizing process ensure long‐term safety explore potential broader range medical
Language: Английский
Citations
3
Cells, Journal Year: 2025, Volume and Issue: 14(2), P. 84 - 84
Published: Jan. 9, 2025
Hepatocellular carcinoma (HCC) is a heterogeneous tumor associated with several risk factors, non-alcoholic fatty liver disease (NAFLD) emerging as an important cause of tumorigenesis. Due to the obesity epidemics, occurrence NAFLD has significantly increased nearly 30% prevalence worldwide. HCC often arises in background chronic (CLD), such nonalcoholic steatohepatitis (NASH) and cirrhosis. Gut microbiome (GM) alterations have been linked progression development, investigations reporting crucial role for gut-liver axis microbial metabolites promoting CLD. Moreover, GM affects homeostasis, energy status, immune microenvironment, influencing response immunotherapy interesting therapeutic implications. In this review, we summarize main changes derived (e.g., short-chain acids bile acids) occurring patients progression, emphasizing their potential early diagnostic biomarkers prognostic tools. We discuss weight loss effects diet-based interventions healthy lifestyles treatment patients, highlighting impact on restoration intestinal barrier structure. also describe encouraging preclinical findings modulation improve functions CLD, boost antitumor probiotic supplementations or anti-hypercholesterolemic drug treatment), ultimately delay HCC. The development safe effective strategies that target holds promise cancer prevention treatment, especially if personalized options will be considered.
Language: Английский
Citations
2
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(15), P. 8250 - 8250
Published: July 28, 2024
The intricate relationship between the gastrointestinal (GI) microbiome and progression of chronic non-communicable diseases underscores significance developing strategies to modulate GI microbiota for promoting human health. administration probiotics prebiotics represents a good strategy that enhances population beneficial bacteria in intestinal lumen post-consumption, which has positive impact on In addition, dietary fibers serve as significant energy source inhabiting cecum colon. Research articles reviews sourced from various global databases were systematically analyzed using specific phrases keywords investigate these relationships. There is clear association fiber intake improved colon function, gut motility, reduced colorectal cancer (CRC) risk. Moreover, state health reflected reciprocal bidirectional relationships among food, antioxidants, inflammation, body composition. They are known their antioxidant properties ability inhibit angiogenesis, metastasis, cell proliferation. Additionally, they promote survival, immune inflammatory responses, inactivate pro-carcinogens. These actions collectively contribute role prevention. different investigations, supplements containing vitamins have been shown lower risk types. contrast, some evidence suggests taking can increase cancer. Ultimately, collaborative efforts immunologists, clinicians, nutritionists, dietitians imperative designing well-structured nutritional trials corroborate clinical efficacy therapy managing inflammation preventing carcinogenesis. This review seeks explore interrelationships fiber, microbiome, with particular focus potential implications
Language: Английский
Citations
12
Cell Biochemistry and Function, Journal Year: 2024, Volume and Issue: 42(4)
Published: May 14, 2024
Colorectal cancer (CRC) is a common digestive tract tumor, with incidences continuing to rise. Although modern medicine has extended the survival time of CRC patients, its adverse effects and financial burden cannot be ignored. multi-step process can caused by disturbance gut microbiome chronic inflammation's stimulation. Additionally, presence precancerous lesions also risk factor for CRC. Consequently, scientists are increasingly interested in identifying multi-target, safe, economical herbal natural products. This paper summarizes berberine's (BBR) regulatory mechanisms occurrence development The findings indicate that BBR regulates homeostasis controls mucosal inflammation prevent In stage, inhibits cell proliferation, invasion, metastasis, blocks cycle, induces apoptosis, metabolism, angiogenesis, enhances chemosensitivity. plays role overall management Therefore, using as an adjunct prevention treatment could become future trend oncology.
Language: Английский
Citations
9
Endocrine and Metabolic Science, Journal Year: 2025, Volume and Issue: unknown, P. 100215 - 100215
Published: Jan. 1, 2025
Citations
1
Nutrients, Journal Year: 2025, Volume and Issue: 17(5), P. 801 - 801
Published: Feb. 26, 2025
Background/Objectives: Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder. Emerging evidence implicates gut microbiota dysbiosis in IBS pathogenesis, and probiotic interventions targeting microbial modulation hold therapeutic promise. Methods: this study used fecal transplantation to establish mouse model of before evaluating the effects complex by using metagenomics targeted metabolomics explore potential mechanism. Results: After 14 days, relieved constipation, reduced inflammation intestinal permeability, lowered 5-HT levels increased serotonin transporter (SERT) expression tissues. Metagenomic analysis showed inflammation-related species abundance. It also decreased butyric acid, acetic acid tryptophan mice. Conclusions: The effectively alleviated symptoms mice modulating metabolites, providing insights for future research treatment.
Language: Английский
Citations
1
Therapeutic Advances in Medical Oncology, Journal Year: 2025, Volume and Issue: 17
Published: Jan. 1, 2025
Pancreatic cancer ranks among the most lethal digestive malignancies, exhibiting a steadily increasing incidence and mortality worldwide. Despite significant advances in research, 5-year survival rate remains below 10%, predominantly due to delayed diagnosis limited therapeutic options. Concurrently, gut microbiota—an integral component of host physiology—has emerged as crucial player pathogenesis pancreatic cancer. Mounting evidence indicates that alterations microbial composition function may influence tumor initiation, progression, response therapy. This review provides an in-depth examination intricate interplay between microbiome cancer, highlighting potential diagnostic biomarkers exploring microbiome-targeted strategies improve patient outcomes.
Language: Английский
Citations
1
Archives of Biochemistry and Biophysics, Journal Year: 2024, Volume and Issue: 761, P. 110172 - 110172
Published: Oct. 4, 2024
Language: Английский
Citations
8
Microorganisms, Journal Year: 2024, Volume and Issue: 12(6), P. 1235 - 1235
Published: June 19, 2024
The discovery of immune checkpoints (CTLA-4, PD-1, and PD-L1) their impact on the prognosis oncological diseases have paved way for development revolutionary treatments. These treatments do not combat tumors with drugs “against” cancer cells but rather support enhance ability system to respond directly tumor growth by attacking lymphocytes. It has now been widely demonstrated that presence an adequate response, essentially represented number TILs (tumor-infiltrating lymphocytes) present in mass decisively influences response disease. Therefore, immunotherapy is based cannot be carried out without increase lymphocytic at site, thereby limiting nullifying certain evasion mechanisms, particularly those expressed activity (under positive physiological conditions) restrain against transformed cells. Immunotherapy experimental phase decades, its excellent results made it a cornerstone many pathologies, especially when combined chemotherapy radiotherapy. Despite these successes, significant patients (approximately 50%) treatment or develop resistance early on. microbiota, composition, our modulate can treatments, reducing side effects increasing sensitivity effectiveness. Numerous studies published high-ranking journals confirm microbial balance, bacteria capable producing short-chain fatty acids (SCFAs), butyrate, essential only chemoradiotherapy also better and, therefore, prognosis. This opens up possibility favorable modulation microbiota could become complementary standard therapies. brief review aims highlight key aspects using precision probiotics, such as Clostridium butyricum, produce butyrate improve checkpoint thus, diseases.
Language: Английский
Citations
4